Achieve Life Sciences (ACHV) Net Cash Flow (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Net Cash Flow of $7.4 million in Q1 2026, up 166.78% on a QoQ basis from -$11.0 million in Q4 2025, and up 2679.25% year-over-year from $265000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Net Cash Flow (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Net Cash Flow across 17 years of filings, most recently posting $7.4 million for Q1 2026.
- Quarterly Net Cash Flow rose 2679.25% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.0 million (down 281.44% YoY) and the FY2025 annual result came in at $8.1 million, up 388.27% from the prior year.
- Net Cash Flow advanced to $7.4 million in Q1 2026, from -$11.0 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $50.8 million in Q1 2024 and troughed at -$20.0 million in Q3 2025.
- A 5-year average of -$555000.0 and a median of -$5.1 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow slumped 443.55% — and 2026, when it soared 2679.25%.
- Tracing ACHV's Net Cash Flow over 5 years: stood at $6.6 million in 2022, then sank by 166.51% to -$4.4 million in 2023, then jumped by 173.46% to $3.2 million in 2024, then sank by 443.55% to -$11.0 million in 2025, then jumped by 166.78% to $7.4 million in 2026.
- Business Quant data shows ACHV's Net Cash Flow at $7.4 million in Q1 2026, -$11.0 million in Q4 2025, and -$20.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 664,983.53 |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | 7.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.37 Mn |
| Mar 31, 2026 | 7.37 Mn |
| Dec 31, 2025 | -11.03 Mn |
| Dec 31, 2025 | -11.03 Mn |
| Sep 30, 2025 | -19.96 Mn |
| Sep 30, 2025 | -19.96 Mn |
| Jun 30, 2025 | -2.37 Mn |
| Jun 30, 2025 | -2.37 Mn |
| Mar 31, 2025 | 265,000.00 |
| Mar 31, 2025 | 265,000.00 |
| Dec 31, 2024 | 3.21 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Sep 30, 2024 | -5.21 Mn |
| Sep 30, 2024 | -5.21 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Mar 31, 2024 | 50.82 Mn |
| Mar 31, 2024 | 50.82 Mn |
| Dec 31, 2023 | -4.37 Mn |
| Dec 31, 2023 | -4.37 Mn |